AI is increasingly recognized as a pivotal element in healthcare, influencing areas such as molecule design, drug trials, and aging research. According to NS3.AI, Pfizer, Anthropic, and longevity researchers have highlighted AI's transformative potential in these fields. Albert Bourla, Pfizer's CEO, mentioned that the company is currently evaluating a new molecule designed using AI technology. Despite the promising advancements, researchers have noted that regulation, computational limitations, and the inherent complexity of biological systems continue to pose challenges to progress.